You are here

  • Home
  • Archive
  • Volume 92, Issue 2
  • Raltegravir-based HIV postexposure prophylaxis (PEP) in a real-life clinical setting: fewer drug–drug interactions (DDIs) with improved adherence and tolerability

Article metrics

Article menu
Download PDFPDF
Letter
Raltegravir-based HIV postexposure prophylaxis (PEP) in a real-life clinical setting: fewer drug–drug interactions (DDIs) with improved adherence and tolerability

 

Online download statistics by month:

Online download statistics by month: February 2016 to March 2024

AbstractFullPdf
Feb 20161871144
Mar 201657628
Apr 201643633
May 20163413
Jun 20162028
Jul 20161978
Aug 2016541019
Sep 201620117
Oct 20165188
Nov 201662108
Dec 20162187
Jan 20171525
Feb 20172663
Mar 20174364
Apr 201710054
May 20172320
Jun 20172132
Jul 20173333
Aug 20172743
Sep 20173341
Oct 20173555
Nov 20174723
Dec 20172810
Jan 20184276
Feb 20181800
Mar 20184632
Apr 20183222
May 20182831
Jun 20184041
Jul 20184132
Aug 20182830
Sep 20182411
Oct 20183010
Nov 20183511
Dec 20183833
Jan 20193452
Feb 20196043
Mar 20192222
Apr 20191521
May 20192542
Jun 20195420
Jul 20194510
Aug 20193560
Sep 20191523
Oct 20193700
Nov 20194952
Dec 20196600
Jan 20205800
Feb 20202420
Mar 20201211
Apr 20202143
May 20202321
Jun 20201800
Jul 20201400
Aug 20202510
Sep 20208222
Oct 20202501
Nov 20202823
Dec 20202724
Jan 20212612
Feb 20211700
Mar 20212521
Apr 2021601
May 20212300
Jul 2021110
Aug 2021210
Sep 2021100
Oct 20213100
Nov 20213500
Dec 20213110
Jan 20222831
Feb 20222800
Mar 20224210
Apr 20223741
May 20225000
Jun 20225140
Jul 20222811
Aug 20225941
Sep 20224432
Oct 20224920
Nov 20224210
Dec 20223120
Jan 202346130
Feb 20238822
Mar 20232810
Apr 20232710
May 20234241
Jun 20232410
Jul 20232611
Aug 20235941
Sep 20235591
Oct 20235151
Nov 20234190
Dec 20233310
Jan 20242811
Feb 202414081
Mar 20241230
Total3602297274